The state of the stent: Current practices, controversies, and future trends

American Journal of Cardiology

Volumn 78, Issue 3 A, 1996, Pages 4-7

  Serruys, Patrick W ^a   Kutryk, Michael J B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NITRIC OXIDE; PHOSPHORYLCHOLINE; TICLOPIDINE; TRAPIDIL;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HUMAN; INTERVENTIONAL RADIOLOGY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

EID: 0029821777     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00485-7     Document Type: Conference Paper

References (11)

1. Sawa H, Vinogradsky B, Guala A, Fujii S. Genetically engineered endothelial cells: increased surface fibrinolysis and potential adaptation to endovascular stenting. Circulation 1995;92(suppl I):I536.
2. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995;91:2995-3001.
3. Goy JJ, Eeckhout E, Debbas N, Stauffer JC, Vogt P. Stenting of the right coronary artery for de novo stenosis. A comparison of the Wiktor and the Palmaz-Schatz stents. Circulation 1995;92(suppl I):I596.
4. Topol EJ. Caveats about elective coronary stenting. (Editorial.) N Engl J Med 1994;331:539-541.
5. Carrié D, Keane D, Elbaz M, Serruys PW, Puel J. Five year clinical and angiographic follow-up of the coronary Wallstent. Circulation 1995;92(suppl I):I409.
6. Debbas N, Sigwart U, Eeckhout E, Stauffer JC, Vogt P, Goy JJ. Late clinical follow-up 9 years after intracoronary stenting with the Wallstent. Circulation 1995;92(suppl I):I280.
7. Pietersma A, Kofflard M, de Wit LEA, Stijnen T, Koster JH, Serruys PW, Sluiter W. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995;91:1320-1325.
8. DEBATE Study Group. Doppler guide wire as a primary guide wire for PTCA. Feasibility, safety and continuous monitoring of the results. Circulation 1995;92(suppl I):I263.
9. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
10. Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Goy JJ, Materne P, Bonnier H, Morice MC, Fajadet MD, Belardi J, Colombo A, Garcia E, Ruygrok P, de Jaegere P, Morel MA, on behalf of the Benestent-II Study Group. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II pilot study. Circulation 1996;93:412-422.
11. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rossow S, Rosenfield K, Weir L, Brogi E. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. (News.) Circulation 1995;91:2687-2692.